Melanoma Treatment in Review

Overview

Journal Immunotargets Ther

Publisher Dove Medical Press

Specialty Allergy & Immunology

Date 2018 Jun 21

PMID 29922629

Citations 271

Authors

Beatriz Domingues

Jose Manuel Lopes

Paula Soares

Helena Populo

Affiliations

Soon will be listed here.

Abstract

Melanoma represents the most aggressive and the deadliest form of skin cancer. Current therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy, immunotherapy, biochemotherapy, and targeted therapy. The therapeutic strategy can include single agents or combined therapies, depending on the patient's health, stage, and location of the tumor. The efficiency of these treatments can be decreased due to the development of diverse resistance mechanisms. New therapeutic targets have emerged from studies of the genetic profile of melanocytes and from the identification of molecular factors involved in the pathogenesis of the malignant transformation. In this review, we aim to survey therapies approved and under evaluation for melanoma treatment and relevant research on the molecular mechanisms underlying melanomagenesis.

Citing Articles

Tangeretin regulates oxidative stress in cutaneous melanoma cells via the Nrf2 signaling pathway.

An Y, Zhang Q, Zhao J, Zheng N Arch Dermatol Res. 2025; 317(1):550.

PMID: 40072600 DOI: 10.1007/s00403-025-03958-w.

Beyond Tuberculosis: The Surprising Immunological Benefits of the Bacillus Calmette-Guérin (BCG) Vaccine in Infectious, Auto-Immune, and Inflammatory Diseases.

Jurczak M, Druszczynska M Pathogens. 2025; 14(2).

PMID: 40005571 PMC: 11857995. DOI: 10.3390/pathogens14020196.

A Unique Signature for Cancer-Associated Fibroblasts in Melanoma Metastases.

Tauch S, Hey J, Kast B, Gengenbacher N, Weiss L, Sator-Schmitt M Pigment Cell Melanoma Res. 2025; 38(2):e70002.

PMID: 39924882 PMC: 11808227. DOI: 10.1111/pcmr.70002.

Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies.

Zhang M, Qiu H, Han Z, Ma Y, Hou J, Yuan J Int J Pharm X. 2025; 9:100316.

PMID: 39898009 PMC: 11787432. DOI: 10.1016/j.ijpx.2025.100316.

Cobalt oxide nanoparticles induce cytotoxicity and excessive ROS mediated mitochondrial dysfunction and p53-independent apoptosis in melanoma cells.

Mohamed H, Mohamed B, Hakeem G, Elnawasani S, Nagy M, Essam R Sci Rep. 2025; 15(1):2220.

PMID: 39820009 PMC: 11739696. DOI: 10.1038/s41598-025-85691-y.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Wolchok J, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L . Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2009; 11(2):155-64. DOI: 10.1016/S1470-2045(09)70334-1. View

Ribas A, Comin-Anduix B, Economou J, Donahue T, de la Rocha P, Morris L . Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009; 15(1):390-9. DOI: 10.1158/1078-0432.CCR-08-0783. View

Deng W, Gopal Y, Scott A, Chen G, Woodman S, Davies M . Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 2011; 25(2):248-58. DOI: 10.1111/j.1755-148X.2011.00950.x. View

Ballantyne A, Garnock-Jones K . Dabrafenib: first global approval. Drugs. 2013; 73(12):1367-76. DOI: 10.1007/s40265-013-0095-2. View

Krieg C, Letourneau S, Pantaleo G, Boyman O . Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A. 2010; 107(26):11906-11. PMC: 2900642. DOI: 10.1073/pnas.1002569107. View

Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B . Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017; 17(5):286-301. DOI: 10.1038/nrc.2017.17. View

Panelli M, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg S . Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother. 2000; 23(4):487-98. DOI: 10.1097/00002371-200007000-00013. View

Kim C, Lee C, Kovacic L, Shah A, Klasa R, Savage K . Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist. 2010; 15(7):765-71. PMC: 3228011. DOI: 10.1634/theoncologist.2009-0237. View

10.

Barton G, Kagan J . A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009; 9(8):535-42. PMC: 3934928. DOI: 10.1038/nri2587. View

11.

Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A . Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009; 15(18):5852-60. PMC: 2745508. DOI: 10.1158/1078-0432.CCR-08-3163. View

12.

Atefi M, Von Euw E, Attar N, Ng C, Chu C, Guo D . Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. PMC: 3237573. DOI: 10.1371/journal.pone.0028973. View

13.

Wilson M, Schuchter L . Chemotherapy for Melanoma. Cancer Treat Res. 2015; 167:209-29. DOI: 10.1007/978-3-319-22539-5_8. View

14.

Populo H, Caldas R, Lopes J, Pardal J, Maximo V, Soares P . Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. Expert Opin Ther Targets. 2015; 19(6):733-45. DOI: 10.1517/14728222.2015.1045416. View

15.

Jacobs J, Nierkens S, Figdor C, de Vries I, Adema G . Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol. 2012; 13(1):e32-42. DOI: 10.1016/S1470-2045(11)70155-3. View

16.

Goff S, Dudley M, Citrin D, Somerville R, Wunderlich J, Danforth D . Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol. 2016; 34(20):2389-97. PMC: 4981979. DOI: 10.1200/JCO.2016.66.7220. View

17.

Huang Y, Vecchio D, Avci P, Yin R, Garcia-Diaz M, Hamblin M . Melanoma resistance to photodynamic therapy: new insights. Biol Chem. 2012; 394(2):239-50. PMC: 3545031. DOI: 10.1515/hsz-2012-0228. View

18.

Flaherty K, Robert C, Hersey P, Nathan P, Garbe C, Milhem M . Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2):107-14. DOI: 10.1056/NEJMoa1203421. View

19.

Zhang E, Xu H . A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J Hematol Oncol. 2017; 10(1):1. PMC: 5210295. DOI: 10.1186/s13045-016-0379-6. View

20.

Hoeflich K, Merchant M, Orr C, Chan J, Otter D, Berry L . Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2011; 72(1):210-9. DOI: 10.1158/0008-5472.CAN-11-1515. View